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Abstract: 
Depleted uranium (DU) is used to reinforce armor shielding and increase penetrability of military munitions. 
Although the data are conflicting, DU has been invoked as a potential etiological factor in Gulf War syndrome. 
We examined regional brain DU accumulation following surgical implantation of metal pellets in male 
Sprague–Dawley rats for 3 or 6 mo. Prior to surgery, rats were randomly divided into five groups: Nonsurgical 
control (NS Control); 0 DU pellets/20 tantalum (Ta) pellets (Sham); 4 DU pellets/16 Ta pellets (Low); 10 DU 
pellets/10 Ta pellets (Medium); 20 DU pellets/0 Ta pellets (High). Rats were weighed weekly as a measure of 
general health, with no statistically significant differences observed among groups in either cohort. At the 
conclusion of the respective studies, animals were perfused with phosphate-buffered saline, pH 7.4, to prevent 
contamination of brain tissue with DU from blood. Brains were removed and dissected into six regions: 
cerebellum, brainstem (pons and medulla), midbrain, hippocampus, striatum, and cortex. The uranium 
content was measured in digested samples as its 
238
U isotope by high-resolution inductively coupled plasma–
mass spectrometry. After 3 mo postimplantation, DU significantly accumulated in all brain regions except the 
hippocampus in animals receiving the highest dose of DU (p < 0.05). By 6 mo, however, significant 
accumulation was measured only in the cortex, midbrain, and cerebellum (p < 0.01). Our data suggest that DU 
implanted in peripheral tissues can preferentially accumulate in specific brain regions. 
Index Entries: Depleted uranium; heavy metal toxicity; Gulf War syndrome; blood–brain barrier transport; 
ICP-MS. 
 
Article: 
INTRODUCTION 
Naturally occurring uranium (U) consists of three isotopes: 
234
U (0.0055%), 
235
U (0.720%), and 
238
U (99.27%). 
During the production of U for nuclear fuel and weapons, the highly radioactive isotope, 
234
U, is enriched, 
leaving the remaining U relatively depleted of both the 
234
U and 
235
U isotopes. This resulting mixture of U, 
known as ―depleted uranium‖ (DU), is mainly the 
238
U isotope (99.8%, with 0.001% 
234
U and 0.20% 
235
U), 
which is 40% less radioactive than natural U and is 1.7 times more dense than lead (Pb). Because of its unique 
physiochemical properties, DU has many civilian and military uses. For example, it is utilized in medical 
equipment radiation shields, aircraft counterbalances, and, until the 1980s, as a component in dental porcelains 
(1). Potential health problems related to DU exposure were highlighted following the first Gulf War (1991) 
because of its use in reinforcing armor plating of military vehicles and as a component in armor-piercing 
munitions. Following service in the Gulf War, many veterans reported various health problems, including 
headaches, dizziness, fatigue, bone and joint pain, muscle weakness, memory loss, problems with sleep and 
concentration, skin rashes and sores, and various gastrointestinal problems (2–4). Together these symptoms are 
known as Gulf War syndrome (GWS). Additional concern regarding health problems resulted following the war 
operations in Serbia, as well as the current use of DU in munitions and shielding in Iraq. 
It is likely that no single chemical or environmental factor/ stressor is responsible for this syndrome, but it has 
been suggested that DU might play a role in the etiology of GWS. Military personnel in the battle arena are 
exposed to a variety of chemicals: organic fumes from petroleum fires, organophosphate pesticides, multiple 
vaccinations in combination with increased inhalation of small particulates (soot, ashes, sand), and high levels 
of stress (4). In general, American Gulf War veterans could have been exposed to DU from several sources: (1) 
inhalation/ ingestion of dust generated during repair, cleaning, or recovery of damaged tanks and armored 
vehicles with DU plating, (2) subcutaneous exposure resulting from injury from ―friendly‖ fire, and (3) 
inhalation/ ingestion of dust generated from collection of DU-containing wartime memorabilia. Interestingly, 
persons with DU shrapnel fragments have high levels of DU in their urine (5–10), although this higher DU level 
does not appear to correlate with decreased neurological function (11). Because it is unknown whether DU is 
found in brain tissue of those with embedded DU fragments, it is important to establish whether DU can 
accumulate in the brains of animals implanted with DU pellets. Evidence of brain accumulation is necessary to 
link DU with the neurological symptoms reported by Gulf War veterans. 
 
Others have implanted DU ―shrapnel‖ in rats (12,13) and measured DU levels in brain, but the animals were not 
perfused prior to removal of the brain. Thus, it is unclear as to what degree the DU levels measured included 
DU from blood present in the brain samples. This is important to consider because blood volume in the 
cerebrovascular tree might represent up to 20% of the total brain volume. To better characterize DU accu-
mulation in brain tissue, we implanted DU pellets in rats to determine whether brain DU levels were greater in 
treated animals compared to nonsurgical controls or rats receiving sham pellets made from tantalum (Ta), an 
inert metal used in various joint replacement surgeries in humans. 
 
MATERIALS AND METHODS  
Chemicals 
Depleted uranium pellets (1 mm in diameter x 2 mm, part no. AOT PN 900397) were obtained from Aerojet 
Heavy Metals (Jonesboro, TN). Tantalum (Ta) pellets (1 mm in diameter x 2 mm, stock no. 77611, lot no. 
A16N11) were made to specification by Alpha Aesar (Ward Hill, MA). 
 
Animals 
The Wake Forest University School of Medicine Animal Care and Use Committee approved all of the animal 
procedures conducted in this study. Adult male Sprague–Dawley rats (Harlan, approx 250 g at study initiation) 
were housed two per cage in an approved laboratory facility under a 12 : 12 light : dark cycle with access to 
food and water ad libitum. Rats were randomly divided into 3- or 6-mo treatment cohorts. Each cohort was fur-
ther divided into five groups: nonsurgical control (NS Control); 0 DU pellets/20 Ta pellets (Sham); 4 DU 
pellets/16 Ta pellets (Low); 10 DU pellets/10 Ta pellets (Medium); 20 DU pellets/0 Ta pellets (High). To assess 
general health during the study, the animals were weighed weekly and observed for signs of morbidity. 
 
Surgical Procedure 
Animals were anesthetized with 12 mg/kg xylazine and 80 mg/kg ketamine prior to surgery. Each 
gastrocnemius was shaved with an electric razor, and the surgical area was cleaned with betadine. Rats were 
covered with a sterile surgical drape for the procedure, and an aseptic technique was followed. Pellets were 
implanted according to a modified method (12). Briefly, an initial incision (approx 3 cm long) was made 
parallel to the muscle. An 18-gage needle was used to produce a guide hole perpendicular to the muscle fibers 
for each pellet. Pellets were implanted to a depth of approx 1 cm. Following the implantation, the incision was 
closed with a suture and antibiotic ointment was applied prior to the animal regaining consciousness. Animals 
were rehydrated with 2 mL sterile isotonic saline injected subcutaneously and then kept in a warmed, insulated 
box until fully conscious (about 45 min postsurgery). Animals were returned to their cages and monitored daily 
for a week for infection and pain, and weekly thereafter until sacrifice. 
 
Tissue Collection 
At the conclusion of the each respective study, rats were anesthetized with 12 mg / kg xylanine and 80 mg / kg 
ketamine. Following anesthetization, animals were perfused with 200 mL phosphate-buffered saline (PBS; pH 
7.4), through the left ventricle, with drainage through the right atrium until effluent was clear. This perfusion 
ensured that brain tissue was relatively free from blood contamination. Brains were removed and immediately 
dissected into six regions: cerebellum (CB), pons/ medulla (grouped together as brainstem [BS]), midbrain 
(MB), striatum (STR), hippocampus (HP), and cortex (CX). Following initial weighing, sections were quick 
frozen on dry ice. Samples were lyophilized prior to analysis. 
 
Inductively Coupled Plasma –Mass Spectrometry 
Concentrated nitric acid (HNO3) (Suprapur, Merck) was added to the lyophilized samples in the following 
amounts: 1 mL HNO3 for 0.05–0.159 g tissue, 2 mL HNO3 for 0.16–0.259 g tissue, 3 mL HNO3 for 0.26–0.359 
g tissue, and 6 mL HNO3 for 0.66–0.96 g tissue. Samples were allowed to sit at room temperature for 24 h prior 
to a 1-h digestion in a block heater at 110 °C. Samples were further digested in a microwave oven (Multiwave 
3000; Anton Paar) at the following specifications: ramp 8 min from 0–130 °C, then holding at 130 °C for 3–6 
min, depending on sample mass. Finally, samples were diluted to 0.6 M HNO3 with 18.2 MQ water. 
 
All brain regions were analyzed for DU content by inductively coupled plasma – mass spectrometry (ICP-MS) 
using a Thermo (Finnigan) model Element 2 instrument (Bremen, Germany), as previously published (14) 
except that radio-frequency power was set at 1300 W. Briefly, the sample was introduced using a CETAC ASX 
510 autosampler (Omaha, USA) with a peristaltic pump (pump speed-1 mL/min). The instrument was equipped 
with a concentric Meinhard nebulizer connected to a Scott spray chamber, and a quartz burner with a guard 
electrode. The nebulizer argon gas flow rate was adjusted daily to give a stable signal with maximum 
intensity for the isotopes 
115
In and 
238
U. The instrument was calibrated using 0.6 M HNO3 solutions of 
multielement standards at appropriate concentrations. After each sample, 0.1 M HNO3 was flushed through the 
sample introduction system to reduce memory effects. To check for possible drift in the instrument, a standard 
solution with known elemental concentrations was analyzed for every 10 samples. In addition, blank samples 
(0.6 M HNO3) were analyzed approximately every 10 samples. The limit of detection (LOD) was 0.4 ng 
238
U/L, 
corresponding to 0.06–0.12 ng 
238
U/g wet mass of tissue. All digested samples were above the LOD. 
 
Statistical Analysis 
One-way analysis of variance (ANOVA), with Tukey’s posttest for multiple comparisons, was used to 
determine whether differences in DU doses affected weight gain during the course of the experiment at each 
time-point. Twoway ANOVA comparing treatment groups at either 3 or 6 mo with each specific brain region 
was performed. Further three-way ANOVAs, with Bonferonni’s posttest for multiple comparisons, examined 
the potential interaction among specific treatment groups in each region at either 3 or 6 mo. For each analysis, 
the overall p-value for the ANOVA is given, as well as the statistical significance of any reported results for dis-
crete regions or treatment groups. Differences among group means was accepted as significant if p ≤ 0.05. Data 
are presented as mean ± SEM, with n = 5–7 animals for each group in each cohort. 
 
RESULTS 
Treatment With DU Does Not Result in Overt Toxicity 
One week postsurgery, visual inspections suggested that animals had fully recovered and were as ambulatory as 
nonsurgical controls (NS Controls). Although there was no significant difference in body mass by the end of the 
respective studies among groups for either the 3- or 6-mo cohorts, DU animals might have consumed greater 
quantities of food. As this was based only on how quickly rodent chow was replaced, it could also be possible 
that DU-treated animals were less efficient in feeding, leading to a greater waste of food pellets. Water 
consumption did not seem to differ from NS Controls for either cohort. 
 
In the 3-mo cohort, Sham rats were initially statistically significantly smaller than the other groups (Fig. 1A). At 
wk 1, one-way ANOVA indicated that the group means were highly statistically significantly different (p < 
0.0001). Specifically, NS Control (p < 0.001), Low and High DU dose rats were different from Shams (p < 0.05 
for both). Additionally, Low, Medium and High groups were different compared to NS Controls (p < 0.05 for 
all). At wk 2, the difference among means was still significant (p < 0.0005): NS Control (p < 0.001) and High (p 
< 0.05) were significantly different compared to Sham, and Low and Medium were different compared to NS 
Control (p < 0.05 for both). By wk 4 and 5, only NS Control (p < 0.01 and p < 0.05, respectively) differed 
compared to Sham. By wk 6, the body masses of the groups were indistinguishable. 
 
Figure 1B indicates that although the mean body mass was not statistically significantly different after wk 5, the 
percentage gain (initial body mass compared to subsequent weeks) differed among groups. One-way ANOVA 
indicated differences among groups for wk 6–12 (see Fig. 1B). Thus, although variations in body mass among 
groups were apparent in the early time-points, differences in percentage mass increase among groups did not 
appear until wk 6. From wk 6 until the conclusion of the 3- mo experiment at wk 12, the mean percentage 
increase in body mass for NS Control was significantly lower compared to Sham (p < 0.05 for wk 6–8, p < 0.01 
for weeks 9–12). Additionally, by wk 9 and continuing until wk 12, the percentage mass gain in the Low group 
was statistically decreased compared to Sham (p < 0.05 for all weeks). 
 
 
 
 
Figure 1C depicts the actual average body mass of the 6-mo group. As for the 3-mo cohort, early differences in 
body masses compared to Sham were observed. At wk 1, one-way ANOVA indicated (p < 0.005) that both 
Medium (p < 0.05) and High (p < 0.01) groups were lighter than the Sham group. One-way ANOVA indicated 
that only animals in the High group remained lighter for wk 2–5 (p < 0.05 for each week) and at wk 9 (p < 
0.01). However, by the conclusion of the experiment at wk 22, the differences in body mass among the groups 
was indistinguishable. 
 
When percentage gain relative to initial body mass was calculated (Fig. 1D), there was no statistically 
significant differences among groups until the last time-point at wk 22. Here, the Medium group was signifi-
cantly different from Sham animals (p < 0.05). 
 
Regional Brain Mass Was Not Different Among Groups 
Two-way ANOVA of the data for the mass (g) of different brain regions from rats in the 3-mo cohort (data not 
shown) indicated that the source of variation among the brain regions was the result of actual differences in 
regional sizes (p < 0.0001). Univariate analysis within brain regions indicated that there were no significant 
differences in wet brain mass among any of the treatment groups. 
 
The results were similar for the 6-mo cohort (data not shown). Although two-way ANOVA indicated that 
differences among group means were solely the result of the differences in regional wet masses (p < 0.0001), 
one-way ANOVA indicated no differences in the mass of specific regions from animals in the respective 
treatment groups. As the body masses of the groups did not differ significantly by the end of either study, brain 
mass was not normalized to body mass. 
 
Regional Brain DU Deposition 
By 3 mo, a dose-dependent pattern of DU accumulation was apparent in the cortex, striatum, brainstem and 
cerebellum (Fig. 2A). Two-way ANOVA indicated that both treatment and regional differences accounted for 
the variation observed in the data (p < 0.0001 for both). DU accumulation was significantly increased (one-way 
ANOVA within brain regions) from animals in the Sham group in the cortex, midbrain (p < 0.001 for both), and 
Striatum (p < 0.01) and was different from NS Control in the brainstem (p < 0.05) for the High group. The DU 
accumulation in the cerebellum was greater than NS Control only in the Medium group (p < 0.05). 
By 6 mo (Fig. 2B), two-way ANOVA indicated variation resulting not only from treatment and regional (p < 
0.0001 for both) differences but also from an interaction between the two (p < 0.01). Univariate analysis within 
the cortex and cerebellum revealed that both the medium (p < 0.001 and p < 0.01, respectively) and High 
groups (p < 0.001 and p < 0.001, respectively) had significantly greater levels of DU compared to Sham 
animals. The accumulation of DU was no longer statistically different from Sham animals in the striatum or 
brainstem, although the midbrain from the high-dose group still had statistically significantly more DU than the 
Sham group (p < 0.01). 
 
 
 
Regional Changes in DU Accumulation Over Time 
Further analysis using three-way ANOVA for treatment, region, and time indicated an overall interaction (p < 
0.02). When the individual analysis for separate comparisons was examined, statistically significant differences 
in DU accumulation over time were observed in the midbrains of Sham animals (p < 0.05) and the cortex (p < 
0.05), hippocampus (p < 0.01), and midbrain and brainstem (p < 0.05 for both) of animals in the low-dose 
group. In general, however, the difference in the amount of DU accumulation in specific regions did not change 
significantly from 3 to 6 mo. This suggests that by 3 mo, DU deposition had either reached a maximum, pro-
tective mechanisms to prevent further metal accumulation had been activated, or that transport of the metal 
across the blood–brain barrier reached a steady-state equilibrium with DU uptake equaling clearance. 
 
DISCUSSION 
Depleted uranium is widely used by the US military (and others) for armor reinforcement and as a component in 
penetration munitions. The long-term effect of DU on soldiers and civilians is unclear. However, US veterans 
returning from areas where DU was used in the combat theater have, along with health care providers, 
expressed concern that health problems related to GWS might be the result of this heavy metal. In order to link 
DU to neurological and neuropsychological signs and symptoms, it is first necessary to demonstrate that DU 
actually crosses the blood–brain barrier (BBB) and accumulates in brain tissue. It is important to demonstrate 
the ability of DU to cross this barrier, as the restrictive nature of the BBB normally confers some degree of 
protection to the brain from the accumulation of foreign and potentially harmful toxicants. 
 
Here, we verify that DU from pellets implanted in muscle indeed crosses the BBB and accumulates to 
statistically significant levels in discrete brain regions, namely the midbrain, striatum, cortex, and cerebellum. 
Similar to our results, others report DU accumulation in the cortex, mid-brain, and cerebellum, but not the 
hippocampus (12), although animals were not perfused prior to removing the brain and determining DU tissue 
levels (12–15). Although DU is higher in the urine of humans with imbedded DU fragments (5,6,8,9,16), no 
data have been reported concerning DU blood levels in this population. Because as much as 20% of the brain 
volume is accounted for by intracranial blood, it is important to determine whether previously reported uranium 
levels in brain tissue were the result of actual tissue accumulation or of blood DU contamination. With this in 
mind, we determined DU levels in the brains of animals that had first been perfused with saline. 
 
In general, the level of DU in the NS Control and Sham groups for various brain regions agreed with previously 
published results (12) using the shrapnel model of exposure. However, our DU levels in brain regions from 
exposed rats are significantly lower than those previously reported. For example, our data indicate that in the 
high group at 3 mo, the total brain DU content is approx 10 ng / g tissue, compared to approx 30 ng / g tissue 
(12). By 6 mo, this difference is even greater in the High group: approx 12 ng / g tissue here, or approx 125 ng / 
g tissue (12). This could be the result of either of the following: (1) DU levels previously reported were higher 
because of residual DU from blood rather than brain tissue levels and (2) the other isotopes of U contribute 
significantly to the amount of metal measured by Pellmar et al. (12), as opposed to the accumulation of 
238
U, 
measured here. The latter is possible, but unlikely because 
234
U and 
235
U contribute only 0.0055% and 0.720%, 
respectively, to the composition of U. Although DU blood levels were not measured in our study, this does not 
detract from the significance of our results, namely that peripherally implanted DU accumulates in the brain.  
Moreover, the phenomenon of heavy metal accumulation reaching a steady-state plateau is not without 
precedent in the literature. For example, rats treated with manganese show a maximum of a twofold to threefold 
accumulation of the metal in the brain, regardless of how long the treatment extends or the dose of the metal 
(17–19). 
 
In both the Pellmar (12) study and ours, overall baseline DU levels, even in Sham animals with Ta pellets, are 
higher in the hippocampus as well as striatum and midbrain, relative to other brain regions. All three of these 
regions are known to be high in transferrin receptor (TfR) and the divalent metal transport 1 (DMT-1). 
Although the mechanism of transport for DU is unknown, some have suggested that DU is associated with the 
TfR (20,21), and both TfR and DMT-1 have been implicated in the transport of iron and manganese, as well as 
other metals (22–26). As our instrumental analysis specifically determines 
238
U, this strongly suggests an 
increased basal accumulation of DU in these discrete brain regions. 
 
Finally, our data confirm the hypothesis that DU can cross the BBB and deposit in the brain parenchyma. 
Unfortunately, determining the cause(s) of GWS is compounded because of the variety of stressors and 
chemicals to which veterans and civilian populations are exposed during a war situation. Currently, only one 
study exists in the literature that examines the behavior of animals following treatment with DU. Briner and 
Murry (27) reported that male rats exposed to depleted uranium acetate in drinking water demonstrated 
increases in rearing and line crossing, suggesting involvement of the dopaminergic system (28). Much more 
work needs to be done in vivo to determine if behaviors in animals correlate with symptoms in human 
populations with DU fragments and if these symptoms are consistent with the regional DU accumulation pat-
terns reported. 
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